- Home
- VEL vs LENZ Comparison
VEL vs LENZ Comparison
Compare VEL & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- LENZ
- Stock Information
- Founded
- VEL 2004
- LENZ 2019
- Country
- VEL United States
- LENZ United States
- Employees
- VEL N/A
- LENZ N/A
- Industry
- VEL Finance: Consumer Services
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- VEL Finance
- LENZ Health Care
- Exchange
- VEL Nasdaq
- LENZ Nasdaq
- Market Cap
- VEL 626.9M
- LENZ 614.9M
- IPO Year
- VEL 2020
- LENZ 2021
- Fundamental
- Price
- VEL $18.79
- LENZ $23.82
- Analyst Decision
- VEL Buy
- LENZ Strong Buy
- Analyst Count
- VEL 5
- LENZ 6
- Target Price
- VEL $20.80
- LENZ $35.40
- AVG Volume (30 Days)
- VEL 72.1K
- LENZ 197.6K
- Earning Date
- VEL 03-06-2025
- LENZ 11-06-2024
- Dividend Yield
- VEL N/A
- LENZ 30.67%
- EPS Growth
- VEL 45.05
- LENZ N/A
- EPS
- VEL 1.84
- LENZ N/A
- Revenue
- VEL $161,829,000.00
- LENZ N/A
- Revenue This Year
- VEL N/A
- LENZ N/A
- Revenue Next Year
- VEL $10.90
- LENZ N/A
- P/E Ratio
- VEL $10.25
- LENZ N/A
- Revenue Growth
- VEL 35.27
- LENZ N/A
- 52 Week Low
- VEL $14.51
- LENZ $2.57
- 52 Week High
- VEL $20.85
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- VEL 35.99
- LENZ 35.08
- Support Level
- VEL $18.57
- LENZ $21.34
- Resistance Level
- VEL $19.06
- LENZ $23.84
- Average True Range (ATR)
- VEL 0.40
- LENZ 1.58
- MACD
- VEL -0.02
- LENZ -0.39
- Stochastic Oscillator
- VEL 14.62
- LENZ 25.78
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.